Monitoring Brain Tumor Metabolism with Cerebrospinal Fluid
Author Information
Author(s): Whitby Alison, Dandapani Madhumita
Primary Institution: Children’s Brain Tumour Research Centre, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, United Kingdom
Hypothesis
Can cerebrospinal fluid metabolites serve as effective biomarkers for monitoring central nervous system tumor progression and treatment response?
Conclusion
Cerebrospinal fluid metabolites have the potential to be used as biomarkers for monitoring brain tumor remission, progression, and treatment response.
Supporting Evidence
- Cerebrospinal fluid analysis is less invasive than surgical biopsy and can provide rapid results.
- Metabolite levels in cerebrospinal fluid can indicate tumor presence and response to treatment.
- CSF metabolomics can help distinguish between treatment reactions and tumor recurrence.
Takeaway
Doctors can check a special fluid around the brain to see if a brain tumor is getting better or worse, which helps them decide how to treat it.
Methodology
This review discusses the potential of cerebrospinal fluid metabolites as biomarkers for brain tumors, focusing on their clinical applicability and the challenges involved.
Limitations
More research is needed to identify and validate specific metabolite biomarkers in a standardized assay.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website